Destiny Pharma
Skip to content
  • Home
  • Company
    • Our Focus
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Vision
  • Need
    • Antibiotic Resistance
    • Post Surgical Infections
    • Incentives for New Antibacterial Drugs
    • Societal Cost
    • Links
  • Platform
    • XF Drug Series
    • XF-73 (exeporfinium chloride)
    • Pipeline
  • Market
  • Investors
    • AIM Rule 26
    • Share Price
    • Regulatory News
    • Company Information
    • Documents
    • Reports & Presentations
    • Advisers
    • Analyst Coverage
    • Corporate Governance
  • News
    • Regulatory news – News
  • Contact
    • Careers
News & Events

Revolutionary Superbug Treatment

 

Continue Reading

Equity Development publish latest research note ‘Destiny Pharma – Bucking the Big Pharma trend’

Posted on 16/04/2019 by Kirsty Richardson

Equity Development publish latest research note, please find link below:-

Destiny Pharma – Bucking the Big Pharma trend

Categories : News
Bookmark the permalink

Post navigation

Previous PostDestiny Pharma welcomes new BEAM Alliance paper “A new vision for AMR innovation to support medical care”
Next PostPosting of Accounts and Notice of AGM

Categories

  • Categories
    • Events
    • News
    • Press Release
    • Uncategorised

    • Archives

    • Archives

    Destiny Pharma

    © All rights reserved.

    Powered by WordPress

    Destiny Pharma plc
    Sussex Innovation Centre
    Science Park Square
    Falmer
    Brighton
    BN1 9SB
    UK

    Tel: +44(0) 1273 704440

    Registered Company
    No. 3167025
    Home
    Company
    Need
    Platform
    Market
    Investors
    News
    Contact
    Terms of Use
    Privacy Statement